Liraglutide combos see greater HbA1c drop

In the January issue of Diabetic Medicine, researchers found that adding Novo Nordisk's liraglutide to glimepiride was more effective at lowering  blood sugar than either glimepiride monotherapy or treatment with  glimepiride plus GlaxoSmithKline's Avandia (rosiglitazone).

Patients on the Danish firm's GLP-1 analog also experienced increased  weight benefit and improved beta-cell function compared to the active  rosiglitazone comparator.

An additional study published recently in Diabetes Care further supports  the efficacy and tolerability profile of liraglutide in the early  treatment of type 2 diabetes, this time when added to metformin and  compared with a glimepiride plus metformin combination.